Cargando…

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

AIMS: Deciding to stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment is challenging, as individual risks of recurrence and bleeding are heterogeneous. The present study aimed to develop and externally validate models for predicting 5-year risks of recurrence an...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Winter, Maria A, Büller, Harry R, Carrier, Marc, Cohen, Alexander T, Hansen, John-Bjarne, Kaasjager, Karin A H, Kakkar, Ajay K, Middeldorp, Saskia, Raskob, Gary E, Sørensen, Henrik T, Visseren, Frank L J, Wells, Philip S, Dorresteijn, Jannick A N, Nijkeuter, Mathilde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079391/ https://www.ncbi.nlm.nih.gov/pubmed/36648242 http://dx.doi.org/10.1093/eurheartj/ehac776

Ejemplares similares

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Menstruation, anticoagulation, and contraception: VTE and uterine bleeding
por: Samuelson Bannow, Bethany, et al.
Publicado: (2021)

Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE study
por: Scheres, LJJ, et al.
Publicado: (2018)

Blood Being Tricky: Anticoagulation-Resistant Venous Thromboembolism (VTE)
por: Tiperneni, Raghu, et al.
Publicado: (2022)

Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study
por: Medina, Andria, et al.
Publicado: (2017)

Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism
por: Klok, Frederikus A., et al.
Publicado: (2019)

Predictive value of venous thromboembolism (VTE)‐BLEED to predict major bleeding and other adverse events in a practice‐based cohort of patients with VTE: results of the XALIA study
por: Klok, Frederikus A., et al.
Publicado: (2018)

Metabolomic Profile in Venous Thromboembolism (VTE)
por: Franczyk, Beata, et al.
Publicado: (2021)

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
por: van der Wall, Sake J., et al.
Publicado: (2018)

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE
por: Jerjes-Sánchez, Carlos, et al.
Publicado: (2021)

Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start)
por: Amin, A., et al.
Publicado: (2009)

Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer‐VTE Registry)
por: Ikeda, Masataka, et al.
Publicado: (2022)

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
por: Ageno, Walter, et al.
Publicado: (2021)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation
por: Khorana, Alok A., et al.
Publicado: (2018)

An anticoagulant that does not cause bleeding – an abrupt stop on the road to the Holy Grail
por: Meijers, Joost C. M., et al.
Publicado: (2019)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Thromboembolic and bleeding complications in patients with oesophageal cancer
por: Mulder, F. I., et al.
Publicado: (2020)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE
por: Schapkaitz, E., et al.
Publicado: (2023)

Extended anticoagulation for VTE: what evidence justifies it?
por: Walia, Anushka, et al.
Publicado: (2023)

One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis)
por: Awano, Nobuyasu, et al.
Publicado: (2022)

Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer
por: Glassman, Deanna, et al.
Publicado: (2022)

Duration of anticoagulant therapy and VTE recurrence in patients with cancer
por: Khorana, Alok A., et al.
Publicado: (2019)

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020)

Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE
por: Ensor, Joie, et al.
Publicado: (2016)

Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?
por: Frere, Corinne, et al.
Publicado: (2020)

Protocol for a systematic review of prognostic models for the recurrence of venous thromboembolism (VTE) following treatment for a first unprovoked VTE
por: Ensor, Joie, et al.
Publicado: (2013)

Venous thromboembolism (VTE) risk assessment completion in psychiatric inpatients
por: Powell, Harriet, et al.
Publicado: (2021)

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis
por: Castellucci, L A, et al.
Publicado: (2014)

On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
por: Haas, Sylvia, et al.
Publicado: (2022)

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
por: Burnett, Allison E., et al.
Publicado: (2016)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

A Survey of Venous Thromboembolism (VTE) Prophylaxis in Obstetrics Patients in Iran
por: Mokhtari, Majid, et al.
Publicado: (2019)

Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE—Results from the ExACT randomised controlled trial.
por: Bradbury, Charlotte, et al.
Publicado: (2019)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

Incidence of Symptomatic Venous Thromboembolism (VTE) in 8,885 Elective Total Hip Arthroplasty Patients Receiving Post-operative Aspirin VTE Prophylaxis
por: Coveney, Eamonn I, et al.
Publicado: (2023)

Venous thromboembolism (VTE) prophylaxis in severely injured patients: an international comparative assessment
por: Gunning, Amy C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5cd6kj6j7qclg4okmvdo1o28eo